Isolation and expansion of human natural T regulatory cells for cellular therapy

Rajendra Pahwa, Shashidhar Jaggaiahgari, Savita G Pahwa, Luca A Inverardi, Andreas Tzakis, Camillo Ricordi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Natural T regulatory cells (nTregs) play a key role in inducing and maintaining immunological tolerance. Cell-based therapy using purified nTregs is under consideration for several conditions, but procedures employed to date have resulted in cell populations that are contaminated with cytokine secreting effector cells. We have established a method for isolation and ex vivo expansion of human nTregs from healthy blood donors for cellular therapy aimed at preventing allograft rejection in organ transplants. The Robosep instrument was used for initial nTreg isolation and rapamycin was included in the expansion phase of cell cultures. The resulting cell population exhibited a stable CD4+CD25++brightFoxp3+ phenotype, had potent functional ability to suppress CD4+CD25negative T cells without evidence of conversion to effector T cells including TH17 cells, and manifested little to no production of pro-inflammatory cytokines upon in vitro stimulation. Boolean gating analysis of cytokine-expressing cells by flow cytometry for 32 possible profile end points revealed that 96% of expanded nTregs did not express any cytokine. From a single buffy coat, approximately 80million pure nTregs were harvested after expansion under cGMP conditions; these cell numbers are adequate for infusion of approximately one million cells kg-1 for cell therapy in clinical trials.

Original languageEnglish
Pages (from-to)67-79
Number of pages13
JournalJournal of Immunological Methods
Volume363
Issue number1
DOIs
StatePublished - Dec 15 2010

Fingerprint

Cell- and Tissue-Based Therapy
Cytokines
T-Lymphocytes
Th17 Cells
Regulatory T-Lymphocytes
Sirolimus
Blood Donors
Population
Allografts
Flow Cytometry
Cell Culture Techniques
Cell Count
Clinical Trials
Transplants
Phenotype
Therapeutics

Keywords

  • Cytokine
  • Expansion
  • IL-2
  • Natural T regulatory cells
  • Rapamycin
  • Suppression

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Isolation and expansion of human natural T regulatory cells for cellular therapy. / Pahwa, Rajendra; Jaggaiahgari, Shashidhar; Pahwa, Savita G; Inverardi, Luca A; Tzakis, Andreas; Ricordi, Camillo.

In: Journal of Immunological Methods, Vol. 363, No. 1, 15.12.2010, p. 67-79.

Research output: Contribution to journalArticle

Pahwa, Rajendra ; Jaggaiahgari, Shashidhar ; Pahwa, Savita G ; Inverardi, Luca A ; Tzakis, Andreas ; Ricordi, Camillo. / Isolation and expansion of human natural T regulatory cells for cellular therapy. In: Journal of Immunological Methods. 2010 ; Vol. 363, No. 1. pp. 67-79.
@article{9d3ab1ec51484377b681833d062c283d,
title = "Isolation and expansion of human natural T regulatory cells for cellular therapy",
abstract = "Natural T regulatory cells (nTregs) play a key role in inducing and maintaining immunological tolerance. Cell-based therapy using purified nTregs is under consideration for several conditions, but procedures employed to date have resulted in cell populations that are contaminated with cytokine secreting effector cells. We have established a method for isolation and ex vivo expansion of human nTregs from healthy blood donors for cellular therapy aimed at preventing allograft rejection in organ transplants. The Robosep instrument was used for initial nTreg isolation and rapamycin was included in the expansion phase of cell cultures. The resulting cell population exhibited a stable CD4+CD25++brightFoxp3+ phenotype, had potent functional ability to suppress CD4+CD25negative T cells without evidence of conversion to effector T cells including TH17 cells, and manifested little to no production of pro-inflammatory cytokines upon in vitro stimulation. Boolean gating analysis of cytokine-expressing cells by flow cytometry for 32 possible profile end points revealed that 96{\%} of expanded nTregs did not express any cytokine. From a single buffy coat, approximately 80million pure nTregs were harvested after expansion under cGMP conditions; these cell numbers are adequate for infusion of approximately one million cells kg-1 for cell therapy in clinical trials.",
keywords = "Cytokine, Expansion, IL-2, Natural T regulatory cells, Rapamycin, Suppression",
author = "Rajendra Pahwa and Shashidhar Jaggaiahgari and Pahwa, {Savita G} and Inverardi, {Luca A} and Andreas Tzakis and Camillo Ricordi",
year = "2010",
month = "12",
day = "15",
doi = "10.1016/j.jim.2010.10.006",
language = "English",
volume = "363",
pages = "67--79",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Isolation and expansion of human natural T regulatory cells for cellular therapy

AU - Pahwa, Rajendra

AU - Jaggaiahgari, Shashidhar

AU - Pahwa, Savita G

AU - Inverardi, Luca A

AU - Tzakis, Andreas

AU - Ricordi, Camillo

PY - 2010/12/15

Y1 - 2010/12/15

N2 - Natural T regulatory cells (nTregs) play a key role in inducing and maintaining immunological tolerance. Cell-based therapy using purified nTregs is under consideration for several conditions, but procedures employed to date have resulted in cell populations that are contaminated with cytokine secreting effector cells. We have established a method for isolation and ex vivo expansion of human nTregs from healthy blood donors for cellular therapy aimed at preventing allograft rejection in organ transplants. The Robosep instrument was used for initial nTreg isolation and rapamycin was included in the expansion phase of cell cultures. The resulting cell population exhibited a stable CD4+CD25++brightFoxp3+ phenotype, had potent functional ability to suppress CD4+CD25negative T cells without evidence of conversion to effector T cells including TH17 cells, and manifested little to no production of pro-inflammatory cytokines upon in vitro stimulation. Boolean gating analysis of cytokine-expressing cells by flow cytometry for 32 possible profile end points revealed that 96% of expanded nTregs did not express any cytokine. From a single buffy coat, approximately 80million pure nTregs were harvested after expansion under cGMP conditions; these cell numbers are adequate for infusion of approximately one million cells kg-1 for cell therapy in clinical trials.

AB - Natural T regulatory cells (nTregs) play a key role in inducing and maintaining immunological tolerance. Cell-based therapy using purified nTregs is under consideration for several conditions, but procedures employed to date have resulted in cell populations that are contaminated with cytokine secreting effector cells. We have established a method for isolation and ex vivo expansion of human nTregs from healthy blood donors for cellular therapy aimed at preventing allograft rejection in organ transplants. The Robosep instrument was used for initial nTreg isolation and rapamycin was included in the expansion phase of cell cultures. The resulting cell population exhibited a stable CD4+CD25++brightFoxp3+ phenotype, had potent functional ability to suppress CD4+CD25negative T cells without evidence of conversion to effector T cells including TH17 cells, and manifested little to no production of pro-inflammatory cytokines upon in vitro stimulation. Boolean gating analysis of cytokine-expressing cells by flow cytometry for 32 possible profile end points revealed that 96% of expanded nTregs did not express any cytokine. From a single buffy coat, approximately 80million pure nTregs were harvested after expansion under cGMP conditions; these cell numbers are adequate for infusion of approximately one million cells kg-1 for cell therapy in clinical trials.

KW - Cytokine

KW - Expansion

KW - IL-2

KW - Natural T regulatory cells

KW - Rapamycin

KW - Suppression

UR - http://www.scopus.com/inward/record.url?scp=78649715490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649715490&partnerID=8YFLogxK

U2 - 10.1016/j.jim.2010.10.006

DO - 10.1016/j.jim.2010.10.006

M3 - Article

VL - 363

SP - 67

EP - 79

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

IS - 1

ER -